Immix Biopharma, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from 2020 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Immix Biopharma, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2020 to 2023.
- Immix Biopharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2024 was -$4.37M, a 22% decline year-over-year.
- Immix Biopharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 30, 2024 was -$19M, a 66.4% decline year-over-year.
- Immix Biopharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$15.4M, a 86% decline from 2022.
- Immix Biopharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$8.27M, a 66.1% increase from 2021.
- Immix Biopharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$24.4M, a 2150% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)